Emergent BioSolutions Inc. — Director's Dealing 2017

Jan 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2017-01-10

Reporting Person: Abdun-Nabi Daniel (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-01	Common Stock	J	1979	$0.0	Acquired	172945	Direct
2016-08-01	Common Stock	J	3032	$0.00	Acquired	175977	Direct
2016-08-01	Common Stock	J	3419	$0.00	Acquired	179396	Direct
2017-01-10	Common Stock	M	38006	$14.51	Acquired	217402	Direct
2017-01-10	Common Stock	S	28240	$31.2782	Disposed	189162	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-01	Stock Option (Right to buy)	$14.51	J	3662	Acquired	2017-03-08	Common Stock (3662)	Direct
2017-01-10	Stock Option (Right to buy)	$14.51	M	38006	Acquired	2017-03-08	Common Stock (38006)	Direct

Footnotes

F1: In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in March 2017.

F2: In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018.

F3: In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019.

F4: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.26, inclusive.

F6: Represents options to purchase Emergent common stock awarded to the reporting person prior to the Spin-off . In connection with the Spin-off, the number of shares and exercise price of the option was adjusted, to preserve the pre-Spin-off intrinsic value of the existing Emergent option award.

F7: Consists of an option granted under the company's stock incentive plan as amended and restated prior to the Spin-off.

F8: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.